Can Wegovy Damage Your Liver? What We Know, What's Uncertain

Step 1 (Understand what the trial data and regulators found

The STEP 1 trial) the pivotal 68-week study that supported Wegovy's UK licence for weight management — did not identify liver injury as an adverse effect of semaglutide 2.4mg. Participants' liver enzymes were monitored throughout, and no clinically meaningful increase was observed in the treated group compared with placebo. You can read the full results in the STEP 1 paper published in the New England Journal of Medicine.

The picture goes further than simply 'no harm'. Fatty liver disease (medically known as metabolic dysfunction-associated steatohepatitis, or MASH) involves fat accumulation and inflammation in liver tissue, often in people with obesity or type 2 diabetes. Because semaglutide reduces body weight and improves metabolic markers, researchers investigated whether it might benefit the liver directly. The answer, in trials of adults with moderate-to-advanced liver fibrosis, was yes. On 3 July 2026, the MHRA granted conditional approval for Wegovy in this MASH indication, making it the first GLP-1 medicine in the UK to hold a licence specifically for liver disease treatment.

That approval covers a narrowly defined patient group under specialist supervision. It does not mean Wegovy is a general liver treatment, and it does not change the weight-management prescribing criteria. But it does tell you that regulators, after scrutinising a substantial body of evidence, concluded that semaglutide does not damage the liver, a question the MHRA examined in detail before granting that licence.

Step 2, Know where genuine uncertainty remains

Honest medicine acknowledges its limits. The main weight-management trials excluded people with severe hepatic impairment, so robust safety data for that group is thin. If your liver function is significantly compromised (for instance, due to cirrhosis) a prescriber cannot rely on the standard trial population to predict how you will respond. That is not a reason to assume Wegovy is unsafe for you; it is a reason the assessment needs to include your liver history.

There is also the gallbladder question. GLP-1 receptor agonists, including semaglutide, slow gastric emptying and can alter bile flow. Gallstones and gallbladder inflammation are listed as known side effects in the Wegovy SmPC. Gallstones can, in some cases, cause secondary liver stress through bile duct obstruction. This is a separate mechanism from direct liver toxicity, but it is worth knowing about. A quick habit worth adopting: if you develop persistent pain in the upper right of your abdomen (especially after eating) check whether it is constant or comes in waves, and contact your prescriber or GP the same day rather than waiting for a routine appointment. It is a symptom that warrants prompt assessment, not watchful waiting.

The relationship between Wegovy and liver health is an active area of research, and people who want a closer look at whether semaglutide causes liver damage will find a dedicated page walking through what the current evidence does and does not show. The NHS medicines page for semaglutide is updated when significant new safety information emerges and is a reliable first reference.

Step 3, Know what to tell your prescriber before starting

A clinical assessment for Wegovy should include your full medical history, including any liver conditions, abnormal liver enzyme results in blood tests, or a diagnosis of fatty liver disease. Mild-to-moderate non-alcoholic fatty liver disease is common in people with obesity and does not automatically exclude you; in many cases the weight loss achieved on treatment actively helps. But the prescriber needs to know.

People with severe hepatic impairment (formally defined in pharmacokinetic terms) are not currently recommended for Wegovy based on available data, and the SmPC reflects this. If you have been told your liver function is seriously impaired, raise this explicitly during your consultation rather than assuming it will be covered by a general health questionnaire, and consider reading our page on whether semaglutide can damage your liver before that conversation so you can ask informed questions.

At nume, a GPhC-registered Independent Prescriber personally reviews every consultation before any treatment is approved. Questions about liver health are part of that clinical picture. If you would like to understand more about how treatment decisions are made, our clinical team page gives you a sense of the oversight behind every prescription. Anyone wanting to explore treatment options can start a free consultation and have their specific circumstances reviewed the same day.

Who should not start Wegovy, and when to seek urgent help

Wegovy is not recommended during pregnancy, breastfeeding, or when trying to conceive. It is not licensed for people under 18. These are firm exclusions, not nuanced clinical judgements. If your circumstances change in any of these respects after starting treatment, stop and contact your prescriber promptly. There is a separate page covering Wegovy and pregnancy for anyone who needs more detail on that specific situation.

For liver-related symptoms specifically, the signs that need same-day or emergency attention are: jaundice (yellowing of the skin or whites of the eyes), dark urine, severe or worsening upper-right abdominal pain, or clay-coloured stools. These could indicate a gallbladder or bile duct problem rather than a direct drug effect, but either way they should not be managed with over-the-counter remedies or left until the next routine review. Call 111 or attend an urgent care centre.

You can also report any suspected side effects via the MHRA's Yellow Card scheme; this is open to patients as well as healthcare professionals and helps regulators identify patterns that individual cases cannot reveal. Anyone with broader questions about what Wegovy involves can read through the Wegovy overview or visit our FAQs.